U.S. Stock Market Midday Update
iBio fell 21.07%, with increased trading volume. Based on recent key news:
<ol>
<li>
On December 9, iBio's stock price plummeted, despite a previous rise following the announcement of obesity drug trial results. The trial results from U.S. biotech companies Wave Life Sciences and Structure Therapeutics triggered a surge in stock prices, which also benefited iBio. However, as a low-priced stock, iBio has limited market coverage. Analysts have given it a strong buy rating, but the price target still indicates significant upside potential.
</li>
<li>
On December 8, increased market attention on obesity drugs led to stock price fluctuations among related companies. The obesity drugs from Eli Lilly and Novo Nordisk are highly popular in the market, impacting iBio's market performance.
</li>
<li>
On December 7, analysts' ratings for iBio failed to drive the stock price up. Despite a strong buy rating from analysts, the market remains cautious about its future performance. The biotech industry has seen significant volatility recently, which requires attention.
</li>
</ol>
Top Stocks by Trading Volume in the Industry
AbbVie fell 0.88%. Based on recent news:
<ol>
<li>
On December 10, HSBC upgraded AbbVie's rating to Buy and raised the target price from $225 to $265. This rating upgrade reflects market confidence in AbbVie's future growth potential, driving a short-term increase in stock price.
</li>
<li>
On December 11, AbbVie announced a 13-year consecutive dividend increase, with a compound annual growth rate of 13%. This news bolstered investor confidence in the company's long-term earnings, further supporting the stock price.
</li>
<li>
On December 12, market analysis indicated that although AbbVie is currently rated as moderately buy, top analysts believe there are five other stocks that are more worthy of investment. This perspective may have negatively impacted some investors' confidence, leading to a slight decline in stock price. Market volatility has intensified, with increased expectations for Federal Reserve interest rate cuts.
</li>
</ol>
Aliram Pharmaceuticals fell 4.31%. Based on recent key news:
<ol>
<li>
On December 10, Aliram Pharmaceuticals oscillated around key support levels, with signs of main funds gradually entering. Community discussions are hot on the topic of its potential &#34;breakthrough,&#34; and although the overall enthusiasm in the pharmaceutical sector is low, the willingness to bottom-fish has increased with market rotation. The MACD and volume-price structure indicate that the bullish base is basically solid, but whether the short-term bulls can truly break through depends on whether they can increase volume and maintain rhythm in the next steps. Source: Zhitong Finance
</li>
<li>
On December 11, Aliram announced a partial repurchase of convertible senior notes maturing in 2027. The company will pay approximately $51.9 million in cash, including accrued and unpaid interest. The repurchase is expected to close shortly after the measurement period, subject to customary closing conditions. Source: Reuters
On December 10th, the innovation drug sector's activity level has warmed up again, with Alibaba's Lam expected to be event-driven at any time. The key point on the market is in the $175 range; if it falls below this level, it will accelerate the decline, while holding above it may lead to a technical rebound. Source: Wall Street Journal. The pharmaceutical sector has recently experienced increased volatility, and attention should be paid to policy changes.
</li>
</ol>
Amgen fell 0.41%, with increased trading volume. Based on recent news,
<ol>
<li>
On December 11th, Wells Fargo raised Amgen's target price from $300 to $325, maintaining a &#34;Hold&#34; rating. This move indicates analysts' optimistic outlook on the company's future performance, but it has not significantly boosted the stock price.
</li>
<li>
On December 10th, Amgen announced a dividend of $2.52 per share for the first quarter of 2026, an increase of 5.9% from before. Despite the dividend increase, the market's reaction was tepid, and the stock price did not see a significant rise.
</li>
<li>
On December 12th, the U.S. Food and Drug Administration approved Amgen's UPLIZNA drug for the treatment of generalized myasthenia gravis. This approval is expected to enhance the company's market share in this field, but its short-term impact on the stock price is limited. The pharmaceutical industry has recently performed steadily, with stable macroeconomic data.
</li>
</ol>
Stocks ranked at the top of the industry by market capitalization
Gilead Sciences fell 0.46%. Based on recent key news:
<ol>
<li>
On December 12th, Gilead Sciences and Arcus Biosciences announced the cessation of a study on a late-stage cancer drug combination, which failed to show survival advantages. This news led to a slight decline in Gilead's stock price.
</li>
<li>
On December 11th, HSBC raised Gilead Sciences' target price from $110 to $133, showing market confidence in its future performance.
</li>
<li>
On December 12th, several executives at Gilead Sciences submitted reports on stock changes, indicating increased insider trading activity, which may affect market sentiment. The biotechnology sector has recently experienced significant volatility and requires attention
</li>
</ol>

IBIO

iBio fell 21.07%; AbbVie fell 0.88%, with a transaction volume of USD 216 million; Alibaba's Lam Pharmaceutical fell 4.31%, with a transaction volume of USD 155 million; Amgen fell 0.41%, with a transaction volume of USD 149 million; Gilead Sciences fell 0.46%, with a market value of USD 152.1 billion

U.S. stock market midday update: Obesity drug trial results fail to boost, iBio stock price plummets 21.07%